Back
HFA Premium Access

Dose-dependent impact of sacubitril/valsartan on left ventricular ejection fraction and survival in patients with heart failure with reduced ejection fraction

Session: Heart Failure ePosters - focus on Chronic Heart Failure 5
Topic: Pharmacotherapy
Speaker: Doctor T. Furlan (Trbovlje, SI)
Event: Heart Failure 2022

Congress Presentation

Add to my library

Like

About the speaker

Doctor Tjasa Furlan

Trbovlje General Hospital, Trbovlje (Slovenia)
0 follower

32 more presentations in this session

Comparison 8 vs. 10mm fenestration size of the atrial flow regulator in patients with heart failure with reduced and preserved ejection fraction: an analysis of the Prelieve Trial

Speaker: Doctor C. Paitazoglou (Luebeck, DE)

Access
Abstract
Slides
Like
Thumbnail

HDAC6 inhibition reduces cardiac fibrosis, enhances mitochondrial function and demonstrates comparable efficacy as empagliflozin in a mouse model of heart failure with preserved ejection fraction

Speaker: Mr J. Yang (South San Francisco, US)

Access
Abstract
Slides
Like
Thumbnail

Improved vascular function after ventricular assist device implantation

Speaker: Doctor D. Nebunu (Zurich, CH)

Access
Abstract
Slides
Like
Thumbnail

Left-heart reverse remodeling patterns following treatment with sacubitril/valsartan

Speaker: Doctor A. Abboud (Boston, US)

Access
Abstract
Slides
Like
Thumbnail

Identifying distinct clinical subgroups in heart failure with mildly reduced ejection fraction

Speaker: Assistant Professor A. Uijl (Amsterdam, NL)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Heart Failure ePosters - focus on Chronic Heart Failure 5

Speakers: Doctor T. Furlan, Doctor C. Paitazoglou, Mr J. Yang, Doctor D. Nebunu, Doctor A. Abboud...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources